Advertisement

Topics

IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib

04:11 EDT 17 May 2018 | Pharmaceutical Business Review

Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.

Original Article: IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib

NEXT ARTICLE

More From BioPortfolio on "IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib"

Advertisement
Quick Search
Advertisement
Advertisement